Search

Your search keyword '"De Laere, Bram"' showing total 6 results
Start Over Author "De Laere, Bram" Publication Year Range This year
6 results on '"De Laere, Bram"'

2. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Author

Fonseca, Nicolette M., primary, Maurice-Dror, Corinne, additional, Herberts, Cameron, additional, Tu, Wilson, additional, Fan, William, additional, Murtha, Andrew J., additional, Kollmannsberger, Catarina, additional, Kwan, Edmond M., additional, Parekh, Karan, additional, Schönlau, Elena, additional, Bernales, Cecily Q., additional, Donnellan, Gráinne, additional, Ng, Sarah W. S., additional, Sumiyoshi, Takayuki, additional, Vergidis, Joanna, additional, Noonan, Krista, additional, Finch, Daygen L., additional, Zulfiqar, Muhammad, additional, Miller, Stacy, additional, Parimi, Sunil, additional, Lavoie, Jean-Michel, additional, Hardy, Edward, additional, Soleimani, Maryam, additional, Nappi, Lucia, additional, Eigl, Bernhard J., additional, Kollmannsberger, Christian, additional, Taavitsainen, Sinja, additional, Nykter, Matti, additional, Tolmeijer, Sofie H., additional, Boerrigter, Emmy, additional, Mehra, Niven, additional, van Erp, Nielka P., additional, De Laere, Bram, additional, Lindberg, Johan, additional, Grönberg, Henrik, additional, Khalaf, Daniel J., additional, Annala, Matti, additional, Chi, Kim N., additional, and Wyatt, Alexander W., additional

Published
2024
Full Text
View/download PDF

3. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping

Author

Warner, Evan W., primary, Van der Eecken, Kim, additional, Murtha, Andrew J., additional, Kwan, Edmond M., additional, Herberts, Cameron, additional, Sipola, Joonatan, additional, Ng, Sarah W. S., additional, Chen, Xinyi E., additional, Fonseca, Nicolette M., additional, Ritch, Elie, additional, Schönlau, Elena, additional, Bernales, Cecily Q., additional, Donnellan, Gráinne, additional, Munzur, Aslı D., additional, Parekh, Karan, additional, Beja, Kevin, additional, Wong, Amanda, additional, Verbeke, Sofie, additional, Lumen, Nicolaas, additional, Van Dorpe, Jo, additional, De Laere, Bram, additional, Annala, Matti, additional, Vandekerkhove, Gillian, additional, Ost, Piet, additional, and Wyatt, Alexander W., additional

Published
2024
Full Text
View/download PDF

4. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Author

De Laere, Bram, Crippa, Alessio, Discacciati, Andrea, Larsson, Berit, Persson, Maria, Johansson, Susanne, D’hondt, Sanne, Bergström, R., Chellappa, Venkatesh, Mayrhofer, Markus, Banijamali, Mahsan, Kotsalaynen, Anastasijia, Schelstraete, Céline, Vanwelkenhuyzen, Jan Pieter, Hjälm-Eriksson, Marie, Pettersson, Linn, Ullén, Anders, Lumen, Nicolaas, Enblad, Gunilla, Thellenberg Karlsson, Camilla, Jänes, Elin, Sandzén, Johan, Schatteman, Peter, Nyre Vigmostad, Maria, Olsson, Martha, Ghysel, Christophe, Sautois, Brieuc, De Roock, Wendy, Van Bruwaene, Siska, Anden, Mats, Verbiene, Ingrida, De Maeseneer, Daan, Everaert, Els, Darras, Jochen, Aksnessether, Bjørg Y., Luyten, Daisy, Strijbos, Michiel, Mortezavi, Ashkan, Oldenburg, Jan, Ost, Piet, Eklund, Martin, Grönberg, Henrik, and Lindberg, Johan

Abstract

ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline DNA analysis was performed in patients with metastatic castration-resistant prostate cancer before randomization to androgen receptor pathway inhibitors (ARPIs), taxanes or a physician’s choice control arm. The primary endpoint was the time to no longer clinically benefitting (NLCB). Secondary endpoints included overall survival and (serious) adverse events. Upon reaching the time to NLCB, patients could be re-randomized. The primary endpoint was met after 218 randomizations. ARPIs demonstrated ~50% longer time to NLCB compared to taxanes (median, 11.1 versus 6.9 months) and the physician’s choice arm (median, 11.1 versus 7.4 months) in the biomarker-unselected or ‘all’ patient population. ARPIs demonstrated longer overall survival (median, 38.7 versus 21.7 and 21.8 months for taxanes and physician’s choice, respectively). Biomarker signature findings suggest that the largest increase in time to NLCB was observed in AR(single-nucleotide variant/genomic structural rearrangement)-negative and TP53wild-type patients and TMPRSS2–ERGfusion-positive patients, whereas no difference between ARPIs and taxanes was observed in TP53-altered patients. In summary, ARPIs outperform taxanes and physician’s choice treatment in patients with metastatic castration-resistant prostate cancer with detectable circulating tumor DNA. ClinicalTrials.gov registration: NCT03903835.

Published
2024
Full Text
View/download PDF

5. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer

Author

Sutera, Philip, Song, Yang, Shetty, Amol C., English, Keara, Van der Eecken, Kim, Guler, Ozan Cem, Wang, Jarey, Cao, Yufeng, Bazyar, Soha, Verbeke, Sofie, Van Dorpe, Jo, Fonteyne, Valérie, De Laere, Bram, Mishra, Mark, Rana, Zaker, Molitoris, Jason, Ferris, Matthew, Kiess, Ana, Song, Daniel Y., DeWeese, Theodore, Pienta, Kenneth J., Barbieri, Christopher, Marchionni, Luigi, Ren, Lei, Sawant, Amit, Simone, Nicole, Berlin, Alejandro, Onal, Cem, Tran, Phuoc T., Ost, Piet, and Deek, Matthew P.

Abstract

For patients with metachronous oligometastatic castration-sensitive prostate cancer, tumor genomics may play a role in the mode of progression and pattern of failure after initial therapy for metastatic disease. Specifically, patients with TP53and RB1mutations have a higher likelihood of progression, and TP53, SPOP, and WNT pathway mutations may have a role in metastatic organotropism directing the likelihood of bone and visceral disease progression.

Published
2024
Full Text
View/download PDF

6. Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Author

De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergström R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjälm-Eriksson M, Pettersson L, Ullén A, Lumen N, Enblad G, Thellenberg Karlsson C, Jänes E, Sandzén J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Grönberg H, and Lindberg J

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results